The ontology of imidazoline receptors was first proposed by Bousquet P in 1980s [1] and was classified as I 1 , I 2 , and I 3 (non-I 1 /I 2 ) subtypes. However, deficiency in high selective ligand restrains the illumination of I 1 imidazoline receptor functions. In 2000, Piletz JE screened human hippocampal expression library and found a strong candidate protein for I 1 imidazoline receptor, named "imidazoline receptor antisera-selected" (IRAS) [2] . Concurrently, Alahari SK discovered a protein with identical sequence as IRAS and named it as "nischarin" [3] . Afterward, this protein was proved to be similar with I 1 imidazoline receptor in tissue distribution, ligand-binding property, and intracellular signallings and mediate many processes such as hypotensive effect of rilmenidine, inhibition of opioid addiction, inhibition of cell migration, antiapoptosis, and so on [4] . Herein, we originally generated IRAS conditional knockout mice (IRAS floxed/floxed ) and IRAS null mice (IRAS À/À ), which might be valuable tools for functional exploration of IRAS/nischarin and I 1 imidazoline receptors.
Mouse IRAS gene is located on chromosome 14 and scatters into 21 exons, and we generated IRAS floxed/floxed mice by flanking exon 4 with loxP sites and then obtained IRAS À/À mice by crossing EIIa-Cre mice ( Figure 1A and Data S1 for more details). As for IRAS À/À mice, genotyping with the primer pair 5loxP-f and 3loxP-r could distinguish wild-type, heterozygote, and knockout mice ( Figure 1B ). Sequencing result of the PCR product from 5loxP-f and 3flank primer pair revealed that only a loxP site remained between upstream and downstream homologous arms. In RTqPCR, the amplification curve of IRAS À/À was normal when the primer pair was originated from exon 3 and exon 5; however, the product is smaller than the wild type ( Figure 1C) . Moreover, the amplification curve of IRAS À/À was null when the primer pair was originated from exon 2 and exon 4 ( Figure 1D ). All the results above illustrated the normal transcription and the absence of exon 4 counterpart in the transcription product of IRAS À/À mice, which resulted in a new stop code in the following exon 5. In the Western blot assay, three bands, between 95 and 130 kD, were absent in cerebellum tissue of IRAS À/À mice ( Figure 1E ). As several bands that represent functional IRAS have been reported, including 85 and 33 kD in human and 67 kD in bovine, these characteristic bands were proposed to be the splicing products in mouse cerebellum. All the above declared the functional deletion of IRAS gene.
The IRAS À/À mice were born small compared with wild-type littermates ( IRAS and insulin receptor substrate, which is the intermediate molecule transferring the signal from IGF receptor to the downstream second messages [6] . Therefore, we proposed that IRAS knockout might lead to dysfunction of IGF receptor signaling and, as a consequence, restrict the fetal growth. There was no significant difference between wild-type and IRAS À/À mice in spontaneous locomotion, grip strength, motor coordination (rotarod test), spatial learning and memory (Morris water maze test), and sensorimotor gating function (prepulse inhibition of acoustic startle response test). Moreover, IRAS knockout did not alter the systolic blood pressure and heart rate of conscious mice (14.4 AE 0.7 kPa and 565 AE 45 beats/min for wild-type mice, n = 6; 14.0 AE 0.6 kPa and 553 AE 64 beats/min for knockout mice, n = 9, measured by Softron BP-98A system), which challenged the idea that IRAS/I 1 receptor mediated the central modulation of blood pressure, and the underlying mechanism still needs further investigation. Besides, pain threshold of IRAS À/À was lower than that of wild type in both hot-plate test and tail-flick test, indicating the nociceptive perception was potentiated in IRAS À/À mice ( Figure 2D , E). Additionally, compared with wild-type mice, the analgesia of methadone in IRAS À/À mice was attenuated in 55°C hot-plate test (genotype: P < 0.001, dose: P < 0.001, genotype 9 dose: P = 0.186, two-way ANOVA with repeated measurements for WTday1 vs. KO-day1) ( Figure 2F ). After chronic methadone (10 mg/ kg, sc) treatments, the dose-response curves of methadone analgesia shifted to right and forward in both wild-type and IRAS À/À mice, suggesting the analgesia tolerance developed ( Figure 2F) . Because of the difference of methadone analgesia before tolerance induction between wild-type and knockout mice, we normalized the MPE values of Days 3, 6, and 9 (after chronic methadone treatment) by that of Day 1 (before chronic methadone treatment). The normalized data revealed that IRAS knockout exacerbated chronic methadone-exposure-induced analgesia tolerance (genotype: P < 0.01, treatment: P < 0.01, genotype 9 treatment: P = 0.471, two-way ANOVA with repeated measurements) ( Figure 2G ). Moreover, after chronic methadone (10 mg/kg, sc) treatment for 8 days, naloxone-precipitation-induced withdrawal Postnatal body weights, that is, at weaning (3 weeks, wild type n = 18, knockout n = 33), 7 weeks (wild-type n = 9, knockout n = 8) and 11 weeks (wild type n = 16, knockout n = 14). Mean AE SEM, ***P < 0.001, knockout versus wild-type, two-way ANOVA. The difference between body weights of knockout and wildtype (the lowest curve) reduced a little after 7 weeks, which was a reflection of catch-up growth. (C) Representative embryos at E12.5. The knockout embryo was smaller than wildtype. (D and E) Basal pain threshold in hot-plate test and tail-flick test (wild-type n = 16, knockout n = 14). Mean AE SEM, **P < 0.01 and ***P < 0.001, knockout versus wild-type, two-way ANOVA with repeated measurments followed by Bonferroni post-hoc test. (F) Cumulative dose-response curves of methadone analgesia before (Day 1) and after chronic methadone (10 mg/kg, sc) treatment (Days 3, 6 and 9). n = 8 of each genotype, mean AE SEM. (G) Analgesia of methadone at the dosage of 10 mg/kg (Data were normalized by the corresponding MPE values of pretolerance induction). n = 8 of each genotype, mean AE SEM. **P < 0.01 and ***P < 0.001, knockout versus wild-type, two-way ANOVA with repeated measurments followed by Bonferroni post-hoc test.
jumping was different between the two genotype mice, in which the incidences of jumping were 4 of 8 and 1 of 8 for IRAS À/À and wild-type mice, respectively (P < 0.01, v 2 -test). This result suggested that IRAS knockout exacerbated the development of physical dependence as well. In 1994, Li G discovered agmatine as the endogenous ligand for imidazoline receptors [7] . Our previous works revealed that exogenous agmatine could enhance morphine analgesia and alleviate morphine tolerance and dependence, which may be mediated by IRAS or I 1 imidazoline receptor [8] [9] [10] . Meanwhile, increasing the level of endogenous agmatine resulted in the same effects as exogenous agmatine; decreasing endogenous agmatine or blocking imidazoline receptors resulted in the reverse effects [8] [9] [10] . Therefore, we proposed that "agmatine and imidazoline receptors might be a novel endogenous modulating system for opioid functions." In this study, IRAS À/À mice not only showed a reduction in pain threshold, but also displayed hyporeactive in analgesia and hyperreactive in tolerance and physical dependence to exogenous opioid substances, which was in full consistent with our hypothesis. Therefore, by means of knockout mice, we not only certified that IRAS is a functional molecule in modulating the opioid functions, but also proved the existence of the novel endogenous modulating system for opioid functions, that is, agmatine and I 1 imidazoline receptor.
In conclusion, we generated IRAS knockout mice for the first time. Primary phenotype assays indicated that this protein may play an important role in embryo development, nociceptive perception, and modulation of opioid functions.
